Literature DB >> 31631227

Bone metabolism parameters and inactive matrix Gla protein in patients with obstructive sleep apnea†.

Marino Vilovic1, Zoran Dogas2,3, Tina Ticinovic Kurir1,4, Josip A Borovac1, Daniela Supe-Domic5, Tina Vilovic6, Natalija Ivkovic2, Doris Rusic7, Anela Novak4, Josko Bozic1.   

Abstract

STUDY
OBJECTIVES: The aim of this study was to investigate differences in dual-energy X-ray absorptiometry (DXA) parameters, trabecular bone score (TBS), bone turnover markers and inactive matrix Gla protein (dp-ucMGP) between patients with obstructive sleep apnea (OSA) and healthy controls.
METHODS: This study enrolled 53 male patients diagnosed with OSA, and 50 age- and body mass index (BMI)-matched control subjects. All participants underwent DXA imaging, TBS assessment and blood sampling for biochemical analysis of bone metabolism markers.
RESULTS: Mean apnea-hypopnea index (AHI) score of OSA patients was 43.8 ± 18.8 events/h. OSA patients had significantly higher plasma dp-ucMGP levels in comparison to controls (512.7 ± 71.9 vs. 465.8 ± 50.9 pmol/L, p < 0.001). OSA and control group did not significantly differ regarding standard DXA results, while TBS values were significantly lower in the OSA group (1.24 ± 0.17 vs. 1.36 ± 0.15, p < 0.001). AHI score was a significant independent correlate of plasma dp-ucMGP levels (β ± SE, 1.461 ± 0.45, p = 0.002). In addition, TBS retained a significant relationship with dp-ucMGP values (β ± SE, -93.77 ± 38.1, p = 0.001).
CONCLUSIONS: dp-ucMGP levels are significantly higher in patients with OSA and correlate with disease severity. In addition, TBS values in OSA patients are lower in comparison with the control group and decrease with disease severity. © Sleep Research Society 2019. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.

Entities:  

Keywords:  bone loss; densitometry; sleep disordered breathing; trabecular bone score

Mesh:

Substances:

Year:  2020        PMID: 31631227     DOI: 10.1093/sleep/zsz243

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  6 in total

1.  Assessment of bone mineral density and bone metabolism in young men with obstructive sleep apnea: a cross-sectional study.

Authors:  Jian-Ming Zhao; Bi-Ying Wang; Jie-Feng Huang; Han-Sheng Xie; Meng-Lan Chen; Gong-Ping Chen
Journal:  BMC Musculoskelet Disord       Date:  2022-07-16       Impact factor: 2.562

2.  Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway.

Authors:  Hong Gu; Yiwen Ru; Wei Wang; Guanhui Cai; Lanxin Gu; Junjie Ye; Wei-Bing Zhang; Lin Wang
Journal:  Drug Des Devel Ther       Date:  2022-07-05       Impact factor: 4.319

3.  Potential impact of pediatric obstructive sleep apnea on mandibular cortical width dimensions.

Authors:  Nathalia Carolina Fernandes Fagundes; Fabrizia d'Apuzzo; Letizia Perillo; Andreu Puigdollers; David Gozal; Daniel Graf; Giseon Heo; Carlos Flores-Mir
Journal:  J Clin Sleep Med       Date:  2021-08-01       Impact factor: 4.324

4.  Circulating Levels of Dephosphorylated-Uncarboxylated Matrix Gla Protein in Patients with Acute Coronary Syndrome.

Authors:  Admira Bilalic; Tina Ticinovic Kurir; Marko Kumric; Josip A Borovac; Andrija Matetic; Daniela Supe-Domic; Josko Bozic
Journal:  Molecules       Date:  2021-02-19       Impact factor: 4.411

5.  Bone mineral density alteration in obstructive sleep apnea by derived computed tomography screening.

Authors:  Ilan Shelef; Ariel Tarasiuk; Sharon Daniel; Yafit Cohen-Freud
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

6.  Inactive matrix Gla protein is elevated in patients with inflammatory bowel disease.

Authors:  Darko Brnic; Dinko Martinovic; Piero Marin Zivkovic; Daria Tokic; Marino Vilovic; Doris Rusic; Ivana Tadin Hadjina; Christian Libers; Sandro Glumac; Daniela Supe-Domic; Ante Tonkic; Josko Bozic
Journal:  World J Gastroenterol       Date:  2020-08-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.